Literature DB >> 7897409

Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?

Y Ben-Shlomo1, M G Marmot.   

Abstract

Most previous studies that have examined the survival of patients with parkinsonism have recruited them from specialist centres. No previous study has ever reported cause specific mortality. We report on the mortality of a cohort of 220 parkinsonian patients recruited between 1970 and 1972 from 40 primary health care practices all over England and Wales and matched to 421 controls. At 20 years of follow up, 195 cases (88.6%) and 295 controls (70.1%) were no longer alive (P < 0.001). The median age at death for cases was 77.6 (range 53.8-97.3) and 83.5 (range 55.0-100.1) for controls (P < 0.001). The all cause hazard ratio for cases compared with controls was 2.6 (95% confidence interval (95% CI) 2.2-3.2) controlling for age, sex, and geographical region. There was little difference between men and women. Differences for cause specific mortality also emerged. Both ischemic heart disease (2.3, 95% CI 1.5-3.4) and cerebrovascular disease (3.6, 95% CI 2.2-6.1) showed significantly increased hazard ratios. Possible reasons for these findings are discussed in terms of (a) competing causes of death, (b) a secondary effect of drug treatment, and (c) common aetiological factors for both parkinsonism and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7897409      PMCID: PMC1073364          DOI: 10.1136/jnnp.58.3.293

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  40 in total

1.  ARTERIOSCLEROSIS IN PARKINSONISM.

Authors:  M J EADIE; J M SUTHERLAND
Journal:  J Neurol Neurosurg Psychiatry       Date:  1964-06       Impact factor: 10.154

2.  Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.

Authors:  H Zumstein; J Siegfried
Journal:  Eur Neurol       Date:  1976       Impact factor: 1.710

3.  Epidemiologic studies of Parkinson's disease. 3. A community-based survey.

Authors:  I I Kessler
Journal:  Am J Epidemiol       Date:  1972-10       Impact factor: 4.897

4.  Effect of L-dopa on course of Parkinson's disease.

Authors:  L Curtis; A J Lees; G M Stern; M G Marmot
Journal:  Lancet       Date:  1984-07-28       Impact factor: 79.321

5.  The prevalence, natural history and dementia of Parkinson's disease.

Authors:  M Pollock; R W Hornabrook
Journal:  Brain       Date:  1966-09       Impact factor: 13.501

6.  Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson's disease. A case-control study.

Authors:  R J Marttila; U K Rinne
Journal:  Clin Neurol Neurosurg       Date:  1976       Impact factor: 1.876

7.  Present morality in parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths.

Authors:  S G Diamond; C H Markham
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

8.  Levodopa in Parkinson disease: a long-term appraisal of mortality.

Authors:  C Joseph; J B Chassan; M L Koch
Journal:  Ann Neurol       Date:  1978-02       Impact factor: 10.422

9.  Epidemiology of parkinsonism: incidence, classification, and mortality.

Authors:  A H Rajput; K P Offord; C M Beard; L T Kurland
Journal:  Ann Neurol       Date:  1984-09       Impact factor: 10.422

10.  Long-term responses of Parkinson's disease to levodopa therapy.

Authors:  U K Rinne; V Sonninen; T Siirtola; R Marttila
Journal:  J Neural Transm Suppl       Date:  1980
View more
  39 in total

1.  Using monoamine oxidase type B inhibitors in Parkinson's disease.

Authors:  Yoav Ben-Shlomo; Kailash Bhatia
Journal:  BMJ       Date:  2004-09-11

2.  Parkinson's disease and cerebrovascular disease: is there a link? A neurosonological case-control study.

Authors:  Sandro Zambito Marsala; Manuela Gioulis; Michele Pistacchi; Cecilia Lo Cascio
Journal:  Neurol Sci       Date:  2016-07-09       Impact factor: 3.307

3.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

4.  Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes.

Authors:  C Friedrich; H Rüdiger; C Schmidt; B Herting; S Prieur; S Junghanns; K Schweitzer; C Globas; L Schöls; D Berg; H Reichmann; T Ziemssen
Journal:  J Neural Transm (Vienna)       Date:  2008-09-20       Impact factor: 3.575

Review 5.  How far are we in understanding the cause of Parkinson's disease?

Authors:  Y Ben-Shlomo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

6.  Further evidence of increased risk of mortality of Parkinson's disease.

Authors:  F Tison; L Letenneur; F Djossou; J F Dartigues
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

7.  The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is not associated with Parkinson's disease.

Authors:  D L Harmon; D Ramsbottom; A S Whitehead; Y Ben-Shlomo; G Davey-Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

8.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

9.  Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.

Authors:  I Litvan; C A Mangone; A McKee; M Verny; A Parsa; K Jellinger; L D'Olhaberriague; K R Chaudhuri; R K Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

10.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.